Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Mader, JK; Wong, JC; Freckmann, G; Garcia-Tirado, J; Hirsch, IB; Johnson, SB; Kerr, D; Kim, SH; Lal, R; Montaser, E; O'Donnell, H; Pleus, S; Shah, VN; Ayers, AT; Ho, CN; Biester, T; Dovc, K; Farrokhi, F; Fleming, A; Gillard, P; Heinemann, L; López-Díez, R; Maahs, DM; Mathieu, C; Quandt, Z; Rami-Merhar, B; Wolf, W; Klonoff, DC.
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.
J Diabetes Sci Technol. 2025; 19322968251333441 Doi: 10.1177/19322968251333441 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Mader Julia
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
This consensus report evaluates the potential role of continuous glucose monitoring (CGM) in screening for stage 2 type 1 diabetes (T1D). CGM offers a minimally invasive alternative to venous blood testing for detecting dysglycemia, facilitating early identification of at-risk individuals for confirmatory blood testing. A panel of experts reviewed current evidence and addressed key questions regarding CGM's diagnostic accuracy and screening protocols. They concluded that while CGM cannot yet replace blood-based diagnostics, it holds promise as a screening tool that could lead to earlier, more effective intervention. Metrics such as time above range >140 mg/dL could indicate progression risk, and artificial intelligence (AI)-based modeling may enhance predictive capabilities. Further research is needed to establish CGM-based diagnostic criteria and refine screening strategies to improve T1D detection and intervention.

Find related publications in this database (Keywords)
CGM
teplizumab
stage 2 T1D
artificial intelligence
machine learning
© Med Uni Graz • Impressum